Published in:
10-08-2022 | Original Paper
Basal Cell Adenoma and Basal Cell Adenocarcinoma: a 50-year Experience From a Single Institution
Published in: Head and Neck Pathology | Issue 4/2022
Login to get accessAbstract
Background
Basal cell adenoma (BCA) and adenocarcinoma (BCAd) are two of the least frequent salivary gland tumors. We describe the largest series of these neoplasms, spanning over a period of 50 years (1970–2020), diagnosed and treated in a single Institution.
Methods
Sixty-eight cases were identified. Clinical and pathological data were collected and correlated with outcome.
Results
Forty-one BCA and 27 BCAd were identified. BCA cases had almost pristine prognosis, with only a relapse in a tumor inadequately excised. Ten patients with BCAd developed metastases, and 14 died from the disease. The 2-year and 5-year survival was of 76% and 42%.
Conclusions
The importance of adequate excision is reinforced in BCA, with no recurrences occurring when margins were negative. Contrary to previous reports, BCAd was not associated with a good prognosis. A better understanding of the genetics of these neoplasms may identify therapeutic options when dealing with inoperable or metastatic disease.